Standout Papers

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer 2014 2026 2018 2022 6.9k
  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
    Martin Reck, Delvys Rodríguez‐Abreu et al. New England Journal of Medicine
  2. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
    Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology
  3. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial (2014)
    Martin Reck, R. Kaiser et al. The Lancet Oncology
  4. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
    Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology
  5. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study (2020)
    Charles M. Rudin, Mark M. Awad et al. Journal of Clinical Oncology
  6. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study (2022)
    Michele Maio, Paolo A. Ascierto et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 3 from Science/Nature 73 standout
Sub-graph 1 of 18

Citing Papers

Therapy-induced senescent cancer cells contribute to cancer progression by promoting ribophorin 1-dependent PD-L1 upregulation
2025 Standout
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
2023 Standout
4 intermediate papers

Works of Maya Gottfried being referenced

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
2021 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
Maya Gottfried 7572 10411 1889 1924 155 12.9k
Katsuyuki Hotta 8489 10920 2044 1916 286 13.7k
Scott Gettinger 6665 9980 2783 2654 255 12.8k
Rina Hui 7176 11054 1810 2387 169 13.8k
Delvys Rodríguez‐Abreu 9848 14669 1927 3368 183 17.4k
Joo-Hang Kim 6612 8190 3050 1374 145 11.4k
Ji‐Youn Han 8002 9442 2992 1241 255 12.8k
Sinéad Cuffe 5706 8340 1723 1839 99 10.7k
Tibor Csőszi 5714 8820 1232 1883 81 10.4k
Laura Q.M. Chow 4544 8861 2795 2951 156 12.1k
Gilberto de Castro 5286 7823 1414 1316 212 10.4k

All Works

Loading papers...

Rankless by CCL
2026